Serotonin increases L-type Ca2+ current and SR Ca2+ content through 5-HT4 receptors in failing rat ventricular cardiomyocytes

Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2367-76. doi: 10.1152/ajpheart.01375.2006. Epub 2007 Jul 27.

Abstract

Rats with congestive heart failure (CHF) develop ventricular inotropic responsiveness to serotonin (5-HT), mediated through 5-HT(2A) and 5-HT(4) receptors. Human ventricle is similarly responsive to 5-HT through 5-HT(4) receptors. We studied isolated ventricular cardiomyocytes to clarify the effects of 5-HT on intracellular Ca(2+) handling. Left-ventricular cardiomyocytes were isolated from male Wistar rats 6 wk after induction of postinfarction CHF. Contractile function and Ca(2+) transients were measured in field-stimulated cardiomyocytes, and L-type Ca(2+) current (I(Ca,L)) and sarcoplasmic reticulum (SR) Ca(2+) content were measured in voltage-clamped cells. Protein phosphorylation was measured by Western blotting or phosphoprotein gel staining. 5-HT(4)- and 5-HT(2A)-receptor stimulation induced a positive inotropic response of 33 and 18% (both P < 0.05) and also increased the Ca(2+) transient (44 and 6%, respectively; both P < 0.05). I(Ca,L) and SR Ca(2+) content increased only after 5-HT(4)-receptor stimulation (57 and 65%; both P < 0.05). Phospholamban serine(16) (PLB-Ser(16)) and troponin I phosphorylation increased by 26 and 13% after 5-HT(4)-receptor stimulation (P < 0.05). 5-HT(2A)-receptor stimulation increased the action potential duration and did not significantly change the phosphorylation of PLB-Ser(16) or troponin I, but it increased myosin light chain 2 (MLC2) phosphorylation. In conclusion, the positive inotropic response to 5-HT(4) stimulation results from increased I(Ca,L) and increased phosphorylation of PLB-Ser(16), which increases the SR Ca(2+) content. 5-HT(4) stimulation is thus, like beta-adrenoceptor stimulation, possibly energetically unfavorable in CHF. 5-HT(2A)-receptor stimulation, previously studied in acute CHF, induces a positive inotropic response also in chronic CHF, probably mediated by MLC2 phosphorylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Calcium Channels, L-Type / drug effects
  • Calcium Channels, L-Type / metabolism*
  • Calcium Signaling* / drug effects
  • Calcium-Binding Proteins / metabolism
  • Cardiac Myosins
  • Cardiotonic Agents / metabolism*
  • Coronary Vessels / surgery
  • Disease Models, Animal
  • Heart Failure / etiology
  • Heart Failure / metabolism*
  • Heart Failure / physiopathology
  • Indoles / pharmacology
  • Isoproterenol / pharmacology
  • Ketanserin / pharmacology
  • Ligation
  • Male
  • Myocardial Contraction
  • Myocardial Infarction / complications
  • Myocardial Infarction / metabolism
  • Myocardial Infarction / physiopathology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Myosin Light Chains
  • Phosphorylation
  • Rats
  • Rats, Wistar
  • Receptor, Serotonin, 5-HT2A / metabolism
  • Receptors, Serotonin, 5-HT4 / metabolism*
  • Sarcoplasmic Reticulum / drug effects
  • Sarcoplasmic Reticulum / metabolism*
  • Serotonin / metabolism*
  • Serotonin 5-HT2 Receptor Antagonists
  • Serotonin 5-HT4 Receptor Antagonists
  • Serotonin Antagonists / pharmacology
  • Sulfonamides / pharmacology
  • Time Factors
  • Troponin I / metabolism
  • Ventricular Function* / drug effects

Substances

  • Adrenergic beta-Agonists
  • Calcium Channels, L-Type
  • Calcium-Binding Proteins
  • Cardiotonic Agents
  • Indoles
  • Myosin Light Chains
  • Receptor, Serotonin, 5-HT2A
  • Serotonin 5-HT2 Receptor Antagonists
  • Serotonin 5-HT4 Receptor Antagonists
  • Serotonin Antagonists
  • Sulfonamides
  • Troponin I
  • myosin light chain 2
  • phospholamban
  • Receptors, Serotonin, 5-HT4
  • Serotonin
  • Ketanserin
  • Cardiac Myosins
  • Isoproterenol
  • GR 113808